Roquefort Therapeutics (LON:ROQ) Shares Down 8.9% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares were down 8.9% during trading on Wednesday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.01 ($0.03). Approximately 1,972,329 shares were traded during trading, a decline of 40% from the average daily volume of 3,297,688 shares. The stock had previously closed at GBX 2.20 ($0.03).

Roquefort Therapeutics Price Performance

The firm’s fifty day simple moving average is GBX 2.74 and its 200 day simple moving average is GBX 3.58. The firm has a market cap of £2.55 million, a P/E ratio of -1.65 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insider Activity at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West purchased 400,000 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was purchased at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,600.62). 60.40% of the stock is owned by insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.